Update from the 2013 International Neurofibromatosis Conference.
作者信息
Plotkin Scott R, Albers Anne C, Babovic-Vuksanovic Dusica, Blakeley Jaishri O, Breakefield Xandra O, Dunn Courtney M, Evans D Gareth, Fisher Michael J, Friedman Jan M, Giovannini Marco, Gutmann David H, Kalamarides Michel, McClatchey Andrea I, Messiaen Ludwine, Morrison Helen, Parkinson David B, Stemmer-Rachamimov Anat O, Van Raamsdonk Catherine D, Riccardi Vincent M, Rosser Tena, Schindeler Aaron, Smith Miriam J, Stevenson David A, Ullrich Nicole J, van der Vaart Thijs, Weiss Brian, Widemann Brigitte C, Zhu Yuan, Bakker Annette C, Lloyd Alison C
机构信息
Department of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24.
Abstract
摘要
相似文献
1
Update from the 2013 International Neurofibromatosis Conference.
Am J Med Genet A. 2014 Dec;164A(12):2969-78. doi: 10.1002/ajmg.a.36754. Epub 2014 Sep 24.
2
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Am J Med Genet A. 2014 Mar;164A(3):563-78. doi: 10.1002/ajmg.a.36312. Epub 2014 Jan 17.
3
Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Int J Mol Sci. 2021 May 29;22(11):5850. doi: 10.3390/ijms22115850.
4
2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Am J Med Genet A. 2018 May;176(5):1258-1269. doi: 10.1002/ajmg.a.38675.
5
Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
Clin Cancer Res. 2017 Jun 15;23(12):e54-e61. doi: 10.1158/1078-0432.CCR-17-0590.
6
Targeted next-generation sequencing for differential diagnosis of neurofibromatosis type 2, schwannomatosis, and meningiomatosis.
Neuro Oncol. 2018 Jun 18;20(7):917-929. doi: 10.1093/neuonc/noy009.
7
Expanding schwannomatosis phenotype.
J Neurooncol. 2015 May;122(3):607-9. doi: 10.1007/s11060-015-1739-8. Epub 2015 Feb 8.
8
Chronic Pain in Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis: A Review on Epidemiology, Pathophysiology, Symptomatology and Treatment.
Pain Physician. 2025 Mar;28(2):105-115.
9
From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Am J Med Genet A. 2019 Jun;179(6):1098-1106. doi: 10.1002/ajmg.a.61112. Epub 2019 Mar 25.
10
NF2-related schwannomatosis: A view from within the inner ear.
Hear Res. 2025 May;460:109226. doi: 10.1016/j.heares.2025.109226. Epub 2025 Feb 28.
引用本文的文献
1
Comparison of the frequency of loss-of-function LZTR1 variants between schwannomatosis patients and the general population.
Hum Mutat. 2022 Jul;43(7):919-927. doi: 10.1002/humu.24376. Epub 2022 Apr 14.
2
Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.
Laryngoscope. 2021 Jan;131(1):E259-E270. doi: 10.1002/lary.28671. Epub 2020 May 21.
3
Clinical Management of Children and Adolescents with Neurofibromatosis Type 1 Like Phenotypes and Complex Behavioural Manifestations: A Multidisciplinary and Dimensional Approach.
Case Rep Psychiatry. 2019 Dec 31;2019:4764031. doi: 10.1155/2019/4764031. eCollection 2019.
4
Age-related schwannomatosis with potential exosome-mediated contribution to prostate hyperplasia: a case report and mini-review.
Ther Adv Urol. 2019 Sep 26;11:1756287219875578. doi: 10.1177/1756287219875578. eCollection 2019 Jan-Dec.
5
[Eye involvement in neurofibromatosis].
Ophthalmologe. 2016 May;113(5):443-52. doi: 10.1007/s00347-016-0237-5.
6
Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
Eur Arch Otorhinolaryngol. 2015 Dec;272(12):3857-60. doi: 10.1007/s00405-015-3604-y. Epub 2015 Mar 21.
7
Cerebellar Hypoplasia and Dysmorphia in Neurofibromatosis Type 1.
Cerebellum. 2015 Dec;14(6):642-9. doi: 10.1007/s12311-015-0658-8.
本文引用的文献
1
Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
Pediatr Blood Cancer. 2014 Jun;61(6):982-6. doi: 10.1002/pbc.24873.
2
mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Neuro Oncol. 2014 Apr;16(4):493-504. doi: 10.1093/neuonc/not242. Epub 2014 Jan 10.
3
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
Otol Neurotol. 2014 Jan;35(1):e50-6. doi: 10.1097/MAO.0000000000000239.
4
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Neuro Oncol. 2014 Jan;16(2):292-7. doi: 10.1093/neuonc/not150. Epub 2013 Dec 4.
5
NF1 is a critical regulator of muscle development and metabolism.
Hum Mol Genet. 2014 Mar 1;23(5):1250-9. doi: 10.1093/hmg/ddt515. Epub 2013 Oct 24.
6
Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
Lancet Neurol. 2013 Nov;12(11):1076-83. doi: 10.1016/S1474-4422(13)70227-8. Epub 2013 Oct 1.
7
The RASopathies.
Annu Rev Genomics Hum Genet. 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523. Epub 2013 Jul 15.
8
Can the diagnosis of NF1 be excluded clinically? A lack of pigmentary findings in families with spinal neurofibromatosis demonstrates a limitation of clinical diagnosis.
J Med Genet. 2013 Sep;50(9):606-13. doi: 10.1136/jmedgenet-2013-101648. Epub 2013 Jun 28.
9
Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2.
Clin Cancer Res. 2013 Jul 15;19(14):3856-70. doi: 10.1158/1078-0432.CCR-12-3167. Epub 2013 May 28.
10
Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
Neuro Oncol. 2013 Aug;15(8):1088-95. doi: 10.1093/neuonc/not068. Epub 2013 May 7.
Zotero 插件